To determine the prognostic potential of a 24-gene signature, Sig24, for identifying patients with prostate cancer who are at risk of developing metastases or of prostate cancer-specific mortality (PCSM) after radical prostatectomy (RP).
Introduction
Radical prostatectomy (RP) is a treatment with curative intent that is frequently performed in patients with clinically localized prostate cancer, significantly reducing the risk of metastasis and prostate cancer-specific mortality (PCSM) [1] [2] [3] . Periodic measurement of serum PSA levels after RP can identify disease recurrence at an early stage so that additional treatment such as radiation therapy or androgen deprivation therapy (ADT) can be initiated. There are many patients, however, who would benefit from adjuvant radiation or ADT immediately after RP to prevent the recurrence of ultimately fatal disease [4] [5] [6] . Pathological analysis of the primary tumour is conducted to identify features that indicate the cancer may have metastatic potential, such as invasion of the seminal vesicles or lymph nodes, and extracapsular extension, in addition to the presence of more poorly differentiated tissue architecture as described according to the Gleason grading system. While there are various methods and nomograms to determine risk group, typically >50% of patients classified as high risk will die from prostate cancer within 10 years of RP [7] . Although a lower proportion of patients with low-and intermediate-risk cancer will die from it, there are still many patients in these groups with aggressive cancers that could benefit from adjuvant therapies.
More recently, a number of multi-gene expression panels showing prognostic potential for outcomes such as biochemical recurrence, metastasis or PCSM have been described [8] [9] [10] . Integration of clinical and genomic variables can allow a more detailed understanding of each patient's tumour pathology and their associated risk of adverse events, offering additional information for the identification of high-risk patients before disease recurrence. We recently described the development and validation of a 24-gene signature, referred to as Sig24, that improved the stratification of patients at increased risk of biochemical recurrence after RP [11] . In the present study, we sought to determine whether Sig24 also had prognostic value for the identification of patients at risk of metastasis or PCSM after RP.
Patients and Methods

Patient Cohort
Decipher GRID TM (Genomic Resource Information Database) is a genomic sharing and collaborative research platform for oncology that contains tumour RNA microarray expression profiles for thousands of patients, and was used to assess the expression of the Sig24 genes in primary prostate tumour specimens collected at the time of RP for patients in three independent cohorts: a case-control set of 182 patients from the Cleveland Clinic [12] ; a case-control set of 545 patients from the Mayo Clinic [10, 13] , and a case cohort set of 235 patients from the Mayo Clinic [14] . The institutional review boards of each participating institution approved the research protocols under which the data were collected and shared as part of Decipher GRID TM . The relevant characteristics of each cohort are summarized in Table S1 .
Calculation of Sig24
The assayed specimens in the Cleveland Clinic cohort were prepared by taking two 0.6-mm diameter tissue cores with a biopsy punch tool to sample the primary Gleason grade of the index lesion of the formalin-fixed paraffin-embedded RP block [12] . For both Mayo Clinic cohorts, the assayed specimens were prepared by macrodissecting tumour from surrounding stroma for up to four 10-lm tissue sections of the primary Gleason grade within the index lesion (the lesion with the highest pathological Gleason score [GS]) of the RP [10, 13, 14] . Gene expression analysis for all patients had been conducted previously by GenomeDx using the Affymetrix Human Exon 1.0 ST GeneChip platform, according to manufacturer recommendations [10] . These data were normalized using the Single Channel Array Normalization (SCAN) algorithm as described previously [15] and the Sig24 score for each patient was calculated by combining the expression of the 24 component genes with the relevant coefficient [11] . These genes and coefficients were originally discovered and trained on a cohort of 100 men for the endpoint of biochemical recurrence, and include genes involved in processes such as cell-cycle progression, angiogenesis, apoptosis, chromatin modification and transcription [11] .
Statistical Analyses
Descriptive statistics of variables focused on medians, interquartile ranges (IQRs), 95% CIs, frequencies and proportions, as appropriate. Correlations between Sig24 score and GS were computed using Spearman's rank correlation. In time-to-event analyses, event times were defined as the time from RP to outcome. Time-dependent c-indices were used to evaluate the performance of Sig24 in the Mayo Clinic II cohort using the nearest-neighbour estimator, with a span parameter of 0.001 as described by Heagerty et al. [16] . Decision curve analysis was used to evaluate the net benefit of the combined clinical+Sig24 model across probability thresholds as compared with treat-all or treat-none scenarios [17] . Survival curves were constructed using Kaplan-Meier methods. Univariable and multivariable Cox proportional hazards models were used to evaluate the impact of clinicopathological features and Sig24 score on the outcomes. In the case of the Mayo Clinic II cohort, control patients were re-weighted by the inverse of the sampling fraction (20%) and the Prentice method for case-cohort design was used in the univariable and multivariable models to inflate the variance [18] . Accordingly, the re-weighted Mayo Clinic II cohort was used to determine time-dependent c-indices [19] . For the combination of clinical features with Sig24, Hosmer-Lemeshow analysis was used to verify that the risk predicated by the combined model accurately reflected observed risk in the study population (Fig. S1 ). Optimum Sig24 thresholds for metastasis and PCSM were developed based on the Mayo Clinic I cohort using the Youden index statistic and survival curves were constructed for the Mayo Clinic II cohort using Kaplan-Meier methods. All statistical tests were two-sided and had a significance level of 0.05. Analyses were performed in R v3.1 (R Foundation, Vienna, Austria).
Results
Sig24 Score was Significantly Associated with Aggressive Tumour Pathology
To investigate the association of our gene signature with tumour aggressiveness, we analysed the correlation of Sig24 scores with pathological GS in the Cleveland Clinic, Mayo Clinic I and Mayo Clinic II cohorts. Amongst all cohorts, higher GSs were significantly associated with higher A similar trend was observed for Mayo Clinic I and Mayo Clinic II, although in these cohorts the most apparent increase in Sig24 score occurred when comparing patients with GS ≤7 vs those with GS ≥8 (P < 0.001; Fig. 1B,C) . Across the three cohorts, the majority of patients with a pathological GS ≤6 had a Sig24 score below the median (74.5%, 79 of 106 patients), while patients with a pathological GS ≥8 tended to have Sig24 scores above the median (90.4%, 320 of 354 patients).
Association of Higher Sig24 Scores with Metastatic Disease
To determine the prognostic ability of Sig24, we focused our analyses on the Mayo Clinic II cohort as it included information on time to event that was necessary for survival analysis. Of the 235 patients in the Mayo Clinic II cohort, 76 experienced metastasis (32.3%) with a median (IQR) time to metastasis of 39 (20-62) Fig. 2B,C) . Decision curve analysis indicated that this combined model offered a net benefit across threshold probabilities of 5-20% for metastasis within 5 years (Fig. 2D) .
Univariable analysis showed that Sig24 had a hazard ratio (HR) of 3.60 (95% CI: 2.04-6.37), which meant that Sig24 scores above the median were accompanied by a 3.6-fold greater risk of developing metastasis (P < 0.001; Table S2 ). Other individual variables that were significantly associated with risk of metastasis included pathological GS ≥8, extracapsular extension, seminal vesicle invasion and ADT (Fig. 2E) . When the combined effects of these factors were considered in multivariable analysis, only Sig24 score and pathological GS ≥8 remained significantly associated with risk of metastasis (Fig. 2F ). Of these factors, Sig24 score had the highest HR (3.78, 95% CI: 1.96-7.29, P < 0.001; Table S2 ).
Positive Association of Risk of Prostate CancerSpecific Mortality with Sig24 Score
We also investigated the association of Sig24 score with PCSM, which occurred in 34 of the patients (14.5%) in the Mayo Clinic II cohort. The median (IQR) time to PCSM was 59 (37-79) months and the median (IQR) follow-up among those without PCSM was 84 (60-107) months. Overall, the 5-and 10-year PCSM-free survival rates were 97.5% (95% CI: 96.3-98.6) and 92.7% (95% CI: 90.0-95.6), respectively. The median (IQR) Sig24 score was 0.18 (0.09-0.26) for patients in whom PCSM occurred within the follow-up period, and 0.00 (À0.14-0.12) for those without PCSM (Fig. 3A) , and the Fig. 3B,C) . Decision curve analysis indicated that the combined model offered a net benefit across threshold probabilities of 5-25% for prognosis of PCSM within 10 years (Fig. 3D) .
Individual variables significantly associated with higher risk of PCSM included Sig24 score, pathological GS ≥8, extracapsular extension, seminal vesicle invasion and ADT, with Sig24 score having the highest HR (4.71, 95% CI: 2.02-11.02; P < 0.001; Fig. 3E and Table S3 ). Sig24 score was also significantly associated with PCSM in multivariable analysis (HR 6.54, 95% CI: 2.16-19.83; P < 0.001), as were pathological GS ≥8 (HR 7.41, 95% CI: 2.45-22.40; P < 0.001), extracapsular extension (HR 2.95, 95% CI: 1.01-8.59; P = 0.05), and serum PSA between 10 and 20 ng/mL, which showed an inverse association (HR 0.26, 95% CI: 0.08-0.92; P = 0.04; Fig. 3F and Table S3 ).
Sig24 has Prognostic Potential for Metastasis and Prostate-Cancer-Specific Mortality
To establish the prognostic performance of Sig24, we conducted Kaplan-Meier analyses of the Mayo Clinic II . Decision curve analysis was conducted to determine the net benefit of the combined model vs scenarios in which no prediction models are required or used (D). Univariable (E) and multivariable (F) analyses of Sig24 and other variables relevant to metastasis were carried out using Cox proportional hazards regression (P < 0.05 shown with filled diamonds).
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© 2017 The Authors BJU International © 2017 BJU International cohort using thresholds determined by applying the Youden index statistic to the Mayo Clinic I cohort. These Sig24 thresholds were À0.1322 for metastasis (75% sensitivity, 42% specificity) and À0.0316 for PCSM (54% sensitivity, 64% specificity; Fig. S2 ). The 5-year metastasis-free survival rate for patients with high Sig24 scores was 90.9% (95% CI: 88.5-93.2%) compared with 98.7% (95% CI: 97.3-100.0%) for patients with low Sig24 scores. The 10-year metastasis-free survival rates were 85.4% (95% CI: 81.9-89.0%) and 96.2% (95% CI: 93.5-99.1%) for patients with high and low Sig24 scores, respectively (P < 0.001; Fig. 4A ). The 5-year PCSMfree survival rate for patients with high Sig24 scores was 92.6% (95% CI: 90.1-95.1%) compared with 98.6% (95% CI: 97.4-99.8%) for patients with low Sig24 scores. The 10-year PCSM-free survival rates were 89.1% (95% CI: 85.5-92.9%) and 97.8% (95% CI: 96.2-99.5%) for patients with high and low Sig24 scores, respectively (P < 0.001; Fig. 4B ).
Discussion
In the present study, we evaluated the Sig24 gene panel for prognosis of metastasis and PCSM. We began by establishing that Sig24 scores were significantly associated with pathological GS. As pathological GS is frequently used as a measure of prostate cancer aggressiveness, gene expression by Sig24 could be of particular use in situations where tumour pathology is ambiguous or borderline. When we investigated the direct association between Sig24 and outcome, we found significantly higher scores in patients who went on to develop metastasis or died from prostate cancer. This was further supported by both univariable and multivariable analysis where higher Sig24 scores were significantly associated with an increased risk of metastasis and PCSM, indicating that Sig24 offers prognostic information in addition to other clinical variables. Kaplan-Meier analysis also showed that patients stratified by Sig24 had significantly different metastasis and PCSM outcomes. It is important to note that only the Mayo Clinic II cohort included the time-to-event data that allowed us to study the association of Sig24 with metastasis and PCSM. Further analysis of this association in additional independent cohorts would provide an understanding of how generalizable these results are.
The work of the present study offers a complementary method for determining a patient's risk of disease recurrence, which could promote more specific prognosis and initiation of additional therapies before recurrence is detected. Previous studies have shown that physicians are willing to incorporate multi-gene expression data into their clinical practice to assist in post-RP treatment decisions; both to encourage the initiation of additional treatments in patients identified as high-risk, and to identify low-risk patients who can safely proceed with observation [20] [21] [22] [23] [24] . In a specific example of this, the use of Decipher GC was shown to improve the identification of patients most likely to benefit from adjuvant radiotherapy [25] . This shows a scenario in which adjuvant radiotherapy could be specifically targeted to the patients who will benefit, while avoiding unnecessary treatment for patients who can be safely managed with a salvage approach. The continued investigation of Sig24 will focus on how best to combine it with currently available gene signatures and whether it has particular relevance for other clinical decision points.
Sig24 has been included in Decipher GRID and will be calculated for all Decipher patients as part of GRID, setting the stage for future study of Sig24. In the present study, we have established that the Sig24 score is associated with a higher risk of metastasis and PCSM. Further development of this biomarker panel will focus on the optimum approach for combining Sig24 with available assays to improve the stratification of patients with high-risk prostate cancer. 
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